All posts by imreal

Care.Coach expands avatar deployments to fight COVID-19 loneliness epidemic


Pat Richards and her virtual cat, Bella, met in March 2017 when Bella moved in with Pat to help her remain living healthy at home and stay connected with her primary care team at Element Care PACE.

Pat Richards and her virtual cat, Bella, met in March 2017 when Bella moved in with Pat to help her remain living healthy at home and stay connected with her primary care team at Element Care PACE.

When I started this company eight years ago to help people like my grandmother with loneliness, I could not have predicted social distancing would become the new normal.

Care.Coach, a Silicon Valley healthcare startup, disclosed today details of a rapid expansion of its virtual avatar program for health plans to combat COVID-19’s exacerbation of the loneliness epidemic in the United States. The company, founded in 2012 by Massachusetts Institute of Technology (MIT) graduate Victor Wang, develops virtual avatars that provide companionship to individuals who live with complex health conditions and chronic loneliness. A large body of published research demonstrates that the feeling of loneliness increases morbidity and mortality; in a time of social distancing, self-isolation, and quarantine, loneliness has become a clear public health crisis. Care.Coach is rising to the challenge by providing its customers with as many avatars as are needed to support these at-risk populations.

For the past 8 years, Care.Coach has been working with care providers to help those populations which possess “outsized risk”, focusing on older adults with psychosocial risks such as loneliness, depression, and anxiety, alongside medical risks such as diabetes, hypertension, COPD, heart failure, and medication non-adherence. Now, broadly enforced self-isolation and shelter-in-place policies are increasingly expected to accelerate an already-growing loneliness epidemic across the nation.

Understanding this reality, the Massachusetts Department of Developmental Services (DDS) North Shore Area Office, an existing customer of Care.Coach, asked the company to quickly provide a 4x increase in the number of avatars deployed to individuals, with the goal of better supporting individuals with coping strategies and a way to stay connected while confined to their homes.

Similarly, Element Care’s Program of All-Inclusive Care for the Elderly (PACE) which is both a provider organization and a health plan, is another customer of Care.Coach. Element Care has ordered and is deploying more avatars to better support their hundreds of participants impacted by the shutdown of their PACE Wellness Centers in an effort to reduce the spread of COVID-19.

Bob Wakefield, Element Care’s CEO, stated, “We care for more than 1,000 frail elders who receive comprehensive medical care and socialize with friends at our PACE Wellness Centers, so it presents an enormous challenge when those centers are all closed due to the COVID-19 outbreak and we need to care for our participants in their homes.”

The situation is stressing individuals as much as the healthcare system. “I woke up this morning and realized I am not going anywhere. I thought I could handle this, but I am struggling,” says Gail Sauvan, an Element Care participant. “I have asked Angel [my Care.Coach avatar] to do chair exercises with me as I miss doing them every day at PACE. I also like his jokes as they make me laugh while I am here alone. I am going to do meditation daily with him too to help keep me calm and reduce my chance of having a panic attack.”

Care.Coach provides specialized tablet-based devices that display an avatar of a pet animal, which serves as a non-judgemental, 24×7 available relationship to support complex, high risk patients and health plan members. For these individuals, the Care.Coach avatar has been shown to reduce loneliness, as described by published research studies from Pace University and the University of Washington. Individuals talk naturally with the avatar using their voice, and receive 24×7 psychosocial support and coaching on managing multiple chronic conditions. The system is powered by a specially-trained team of health advocates employed by Care.Coach and supported by evidence-based protocols and artificial intelligence. Traditional care teams are automatically alerted about adverse events and changes in health status, and receive actionable analytics. Each Care.Coach device includes its own cellular Internet connection, so individuals do not need Wi-Fi at home.

“When I started this company eight years ago to help people like my grandmother with loneliness, I could not have predicted social distancing would become the new normal,” says Victor Wang, founder and CEO of Care.Coach. “I’m very proud of our growing team here at Care.Coach for stepping up to the challenge of helping many more individuals and for rapidly scaling up with our Medicare Advantage, PACE, and other customers in this time of great need.”

About Element Care PACE Health Plan

Founded in 1995, Element Care is a non-profit, healthcare organization with a simple mission: to help people live safely and comfortably in their homes and their communities for as long as they can, keeping their stays in hospitals and nursing facilities as minimal as possible. Element Care provides complete health care to eligible people through the Program of All-inclusive Care for the Elderly (PACE) throughout the North Shore, Merrimack Valley and northeast region of Middlesex County in Massachusetts. For more information, visit http://www.elementcare.org

About Massachusetts Department of Developmental Services

The Massachusetts Department of Developmental Services (DDS) provides support for individuals with intellectual and developmental disabilities, including autism spectrum disorder. The DDS’s mission is to create, in partnership with others, innovative and genuine opportunities for individuals with intellectual and developmental disabilities to participate fully as valued members of their community. The DDS serves over 30,000 individuals across its 28 offices throughout Massachusetts. For more information, visit https://www.mass.gov/orgs/department-of-developmental-services

About Care.Coach

Care.Coach is a California-based conversational and relational automation technology company backed by over $7 million in public and private funding from Congress, the NIH, and private investors. The Care.Coach platform, deployed nationally across more than 20 states, combines human empathy, intelligent technology, and an engaging animal avatar to build real relationships with the most complex, high-need individuals within the healthcare system. The avatars leverage these personal relationships to deliver evidence-based coaching, driving value by reducing the need for home nursing visits, reducing emergency department and hospital visits, and improving key health plan quality measures. Care.Coach was named one of the Top 5 IT Innovations of 2019 by the HealthLeaders IT Spending Guide, one of the Best Healthcare Startups to Watch in 2020 by Healthcare Weekly, and one of the Top 10 Aging in Place Innovations by GuideWell in 2020. For more information, visit https://care.coach

Share article on social media or email:

Skinuva™ Brite Launches Non-Hydroquinone Skin-Brightening Cream Founded By Beverly Hills Based Dr. Christopher Zoumalan


We wanted to use our clinical knowledge in developing the most advanced product possible for hyperpigmentation on the market, while clinically testing our product at the highest standards.

Skinuva™ is proud to release Skinuva™ Brite, its second product in its revolutionary growth-factor based topical formulation portfolio. Skinuva™ Brite is non-hydroquinone topical formulation with tailored ingredients including growth factors to help improve hyperpigmentation. Similar to the science utilized in creating Skinuva™ Scar, Skinuva™ Brite uses the latest growth factor technology to provide a safe and effective daily use product for the treatment of hyperpigmentation.

“There has been a recent consumer demand to provide safe and effective non-hydroquinone topical formulations in the treatment of hyperpigmentation,” states CEO and Founder Dr. Christopher Zoumalan, who also practices as a Beverly Hills Oculoplastic Surgeon. “We wanted to use our clinical knowledge in developing the most advanced product possible for hyperpigmentation on the market, while clinically testing our product at the highest standards,” further states Dr. Christopher Zoumalan.

Skinuva™ Brite has been extensively tested and found to be safe and effective in improving hyperpigmentation. Types of hyperpigmentation include melasma, post inflammatory hyperpigmentation, under eye hyperpigmentation and sun spots. Our recent clinical trial showed that Skinuva™ Brite improved the appearance of hyperpigmentation in patients with hyperpigmentation that used the product twice a day for at least one month. Skinuva™ Brite was also shown to be tolerated very well with minimal irritation and redness.

Skinuva™ Brite does not include ingredients known to be potentially harmful to children, babies, or pregnant or nursing women when the product is used as directed.

Skinuva™ Brite can improve the appearance of dark spots and discoloration on the face and body. Skinuva™ Brite should be applied twice a day, morning and night to the affected areas. Sunscreen may be worn over Skinuva™ Brite.

Skinuva™ Brite can be purchased from physician offices that carry the Skinuva™ line, and also online at http://www.skinuva.com.

Share article on social media or email:

Kyash Announces US$45 Million Series C Funding From Global Venture Capital Firms As It Heads Into Banking


Kyash images

We are confident that our focus on developing proprietary payment technology and strategic merchant network partnerships continues to bring value to users and addresses the need for remote financial transactions in a digital economy

Kyash has raised $45 million in a Series C Funding round co-led by Greenspring Associates and Goodwater Capital, a global consumer technology investor along with several venture capital firms from around the world to accelerate its full-stack mobile banking business in Japan. Total funds raised as of today are $73 million.

Investors in the round include Goodwater Capital, which initially invested in Kyash’s Series B Round, Greenspring Associates, a global venture capital investment platform with over $10 billion in assets under management, Greyhound Capital, a UK growth equity investment firm, US venture capital firm Altos Ventures, global investment firm Partech Partners, US FinTech venture capital fund Broadhaven Ventures, US venture capital firm Tekton Ventures, and Mr. Rahul Mehta, Managing Partner of DST Global. This is the first time Greenspring Associates, Partech, and Broadhaven Ventures have invested in a Japanese startup. Previous investor JAFCO also participated and remains committed to supporting Kyash’s vision.

The funding will be used to further Kyash’s overall growth strategy and business domain expansion, particularly into the banking space. ​

Since October 2019, Japan has undergone a nationwide cashless transformation driven by the government’s subsidization of a portion of cashless payments. This transformation has become even more pressing with the onset of the coronavirus pandemic. With social distancing protocols being enforced worldwide, cashless payments are quickly becoming the norm, reducing physical contact and making people’s lives easier, safer, and less stressful during this difficult time.

“I am delighted to announce Kyash’s partnerships with these global investors as a result of the company’s progress in product development and significant user traction in Japan amid the uncertain market conditions resulting from the widespread effects of the pandemic,” said Shinichi Takatori, Founder & CEO of Kyash. “We are confident that our focus on developing proprietary payment technology and strategic merchant network partnerships continues to bring value to users and addresses the need for remote financial transactions in a digital economy.”

About Kyash

Kyash is a Tokyo-based fast growing mobile financial startup that offers a mobile banking experience to consumers. Founded in 2015, the company’s mission is to create a new financial infrastructure to transform the Japanese banking landscape. Kyash’s proprietary payment processing technology facilitates better unit economics and more flexibility around product development. Investors in the company include all three major Japanese mega bank groups, as well as global venture capital firms. Kyash has also made its APIs available to other business partners for their payment services by issuing Visa cards.

Share article on social media or email:

PatientPay Oversubscribes $6M Funding Round


PatientPay Mobile Solution

PatientPay, the leading patient payments partner for acute, ambulatory, and specialty care, today announced it secured $6.15 million in growth financing.

PatientPay, the leading patient payments partner for acute, ambulatory, and specialty care, today announced it secured $6.15 million in growth financing. The investment will be used to significantly expand its ability to serve the needs of Revenue Cycle Management (RCM) companies as well as further enhance its omni-channel patient payments platform.

The round was led by Mosaik Partners and an existing investor, with participation from other current and new investors. This financing supports PatientPay’s industry-leading end-to-end patient engagement and payment solution that captures more payments while making the patient billing experience an integrated part of patient care.

“This new financing will enable PatientPay to bring more innovation and efficiencies in healthcare with electronic strategies for patient payments that serve to drive more payments, lower the cost of care while providing a positive patient experience during the billing process,” said Tom Furr, PatientPay’s CEO.

“PatientPay has been partnering successfully with several of the largest healthcare RCM operations in the country who use our omni-channel strategies to target mobile patient payments via text and email as the initial touch points for healthcare bills. Time and again, we’ve seen when patients understand their financial responsibilities – and feel more in control of their healthcare payment experience – it is a win-win-win equation for them, the RCM and the healthcare provider,” Furr said.

According to a recent report from KeyBank, “The U.S. healthcare industry has been notoriously slow to embrace new payment systems and processes, largely due to the complexity that arises from regulatory and privacy requirements. Only 17% of consumers receive a medical bill electronically, despite over 70% preferring electronic statements.” In stark contrast, PatientPay’s electronic medical billing has yielded the following success metrics:

  • 53% of patient statements are paid in the first 28 days.
  • 60% of electronic bills are paid online.
  • 63% of payments are made via customized payment plans.

PatientPay’s patents and software leverage existing central billing office infrastructure and systems to bill and reconcile patient payments using existing insurance claims data that ultimately simplifies the entire billing process for the patient. This unique architecture enables PatientPay to match patient bills to their insurance’s explanation of benefits (EOB) allowing patients to trust their bill. PatientPay’s flexible payment plan options help patients better manage certain bills that might be difficult to pay in full due to the continual rise of patient financial responsibility. PatientPay RCM clients use integrated analytics to provide smarter collection strategies to better understand how patients navigate and pay their bills.

PatientPay’s platform gives RCM operations visibility into their complete patient payment strategy by utilizing their current eligibility and estimation solution as well as integrating it into their early out call centers. PatientPay has as much as doubled patient payment collections compared to RCM’s prior collection capabilities.

To learn more about how PatientPay drives end-to-end patient payments and, ultimately, value for both patients and providers, visit http://www.patientpay.com.

About PatientPay

PatientPay partners with RCM companies to capture more patient payments faster at every step of the healthcare journey. As patient financial responsibility grows, acute care providers, physician groups and specialty services such as labs, therapy, radiology and anesthesiology rely on PatientPay to get paid more and faster. Ultimately PatientPay aims to extend the patient experience with enhanced overall patient satisfaction by matching bills with EOBs, flexible payment options, and custom communications. Learn more about how PatientPay drives end-to-end patient payments and, ultimately, value for both patients and providers at http://www.patientpay.com.

Share article on social media or email:

Major U.S. Companies Partner with Kabbage to Increase Sales for U.S. Small Businesses During Crisis


News Image

We are committed to doing everything in our power to support U.S. small businesses impacted by COVID-19. In such moments of crisis, organizations have a unique opportunity to come together to help those hit the hardest. It’s heartening to see so many organizations band together…

Kabbage, a data and technology company providing small business cash flow solutions, announces major U.S. companies have joined the http://www.helpsmallbusiness.com initiative to support small businesses during the COVID-19 crisis. Launched on March 18, http://www.helpsmallbusiness.com is empowering hundreds of U.S. small businesses to generate critical revenue through the sale of online gift certificates during this national economic slowdown.

Kabbage is not profiting from this effort, and partners have pledged similar commitments to offer relief and spread the word to aid small businesses, including:

  • Alibaba.com
  • Become.co
  • Brickell Capital Finance
  • Finix
  • GroupRaise
  • Gusto
  • The Hartford
  • Lendio
  • Nav
  • Pledge 1%
  • Small Business Connection
  • Soofa.co
  • StartupNation
  • UPS

The initiative is a call to action across the entire business sector to support small businesses that are most vulnerable to economic shortfalls. Organizations interested in joining these efforts may reach out to partnerships@kabbage.com.

“We are committed to doing everything in our power to support U.S. small businesses impacted by COVID-19,” said Kabbage CEO Rob Frohwein. “In such moments of crisis, organizations have a unique opportunity to come together to help those hit the hardest. It’s heartening to see so many organizations band together and show their unconditional commitment to small businesses.”

About Kabbage

Kabbage, Inc., headquartered in Atlanta, is a data and technology company providing

small businesses cash flow solutions. Its suite of products includes Kabbage Funding™, providing access to flexible lines of credit in minutes; Kabbage Payments™, helping small businesses get paid and access the money they earn faster; and Kabbage Insights™, calculating small business’s real-time cash flow. To date, Kabbage has provided more than 225,000 U.S. small businesses access to over $9.5 billion of working capital. Kabbage is funded and backed by leading investors, including the SoftBank Vision Fund, BlueRun Ventures, Mohr Davidow Ventures and others. All Kabbage Funding U.S.-based loans, including custom loans, are issued by Celtic Bank, a Utah-Chartered Industrial Bank, Member FDIC, and are subject to credit approval. Kabbage Payments, LLC, a subsidiary of Kabbage, Inc., is a registered Payment Service Provider/Payment Facilitator sponsored by Fifth ThirdBank, N.A., Cincinnati, OH. For more information, please visit http://www.kabbage.com.

###

Share article on social media or email:

4medica and KPI Ninja Launch COVID-19 Alerts and Reporting Solution to Identify At-Risk Patients to Support Treatment and Prevention Efforts


News Image

“The COVID-19 Alerts and Reporting Solution make sense of the confusing collection of data to prevent the transmission of COVID-19,” said Gregg Church, president of 4medica.

4medica® and KPI Ninja announced today teaming up to launch a comprehensive lab analytics solution to support rapid treatment, prevention and spread of the COVID-19 (coronavirus) pandemic. The COVID-19 Alerts and Reporting Solution™ helps healthcare organizations and medical professionals identify and prioritize patients at higher risk of contracting severe forms of the respiratory disease. The solution also finds and tracks healthcare facility and ICU bed utilization across the U.S.

The Centers for Disease Control and Prevention (CDC) reports, “In the event of a discrepancy between CDC cases and cases reported by state and local public health officials, data reported by states should be considered the most up to date.” This statement points to a national need for precise data to identify and track suspected or confirmed patient cases concurrently with the availability of bed capacity. First responders, hospitals, health systems, medical practices, ACOs, HIEs and public health agencies need the data insights to make informed decisions mobilizing people and facilities to care for the growing number of cases in various regions across the U.S.

The COVID-19 Alerts and Reporting Solution integrates the 4medica Lab Hub™ and KPI’s Ninja Universe analytics platform to provide real-time lab pandemic analytics and ADT notifications. Commercial laboratories such as Quest Diagnostics, LabCorp, BioReference Laboratories and public health laboratories send results to 4medica to normalize and match to the right patient identity. The validated data is then submitted to the Ninja Universe platform to analyze and share with the appropriate front-line providers, public health agencies and patients.

Nebraska Health Information Initiative (NEHII) is the first health information exchange using the solution to analyze the risk, prevalence and characteristics of COVID-19 cases and perform risk stratification analysis of other social resources and factors impacted by the virus across the state of Nebraska.

“The COVID-19 Lab Alerts and Reporting Solution augments our HIE to report accurate, knowledge-based data that informs life-saving decisions and community emergency prevention efforts at a time of unprecedented need,” said Jaime Bland, NEHII CEO.

“The COVID-19 Alerts and Reporting Solution make sense of the confusing collection of data to prevent the transmission of COVID-19,” said Gregg Church, president of 4medica. “While interoperability is a persistent challenge in the U.S. healthcare system, we’ve proactively built a solution that interprets the data into clear, succinct and actionable knowledge to help healthcare organizations address critical COVID-19 pandemic issues quickly and efficiently.”

“The solution immediately equips frontline healthcare workers with the right, accurate data they need to perform their jobs at the highest level,” said Vineeth Yeddula, CEO of KPI Ninja. “Whether this is a first responder’s having real-time data to locate the best hospital to transfer a patient or a state authority needing a density map to pinpoint case surges regionally, the solution’s detailed output supports decision-makers strategizing and allocating appropriate emergency response and resources for people requiring the greatest amount of aid.”

Journalists: Click here to download a screenshot of COVID-19 Alerts and Reporting Solution.

About 4medica

Guaranteeing an unprecedented 1% patient record duplication rate, 4medica® solves data integrity and financial challenges to minimize patient safety and other clinical risks and achieve true clinical interoperability and transparency for patients. Our Big Data Management and Clinical Data Exchange cloud solutions help healthcare organizations facilitate patient identity management and data exchange to ensure the right data is captured at the right time, the first time. 4medica’s Perfect Order for Perfect Payment™ ensures labs and imaging centers get paid by integrating high-volume revenue cycle management services throughout the entire order management process. 4medica has processed up to 6 billion clinical results representing more than 70 million patient identities. The company connects 40,000-plus physicians to hundreds of ACOs, HIEs, HINs, hospitals, health systems, laboratories, radiology imaging centers and payers nationwide. Learn more at http://www.4medica.com.

About KPI Ninja

KPI Ninja is a healthcare analytics company that supports healthcare organizations to meet their population health and value-based initiatives. Using our signature mix of innovative technology solutions and services, we work shoulder-to-shoulder with clients to accelerate goal achievement. In harmony with our data-centered ethos, we truly believe that our success is strongly correlated with yours. We are differentiated by our comprehensive capabilities that transcend value-based programs and data sources to support stakeholders’ use of data to improve outcomes. Our platform is aligned to initiatives led by CMS, ONC, NCQA, including holding NCQA’s eCQM Certification, Measure Certification for HEDIS® Health Plan 2020, PCMH and PCSP Prevalidation; demonstrating our commitment to providing you a trusted brand.

Share article on social media or email:

Carterra® Inc. Selected by the La Jolla Institute of Immunology to Provide Antibody Screening and Characterization for the Coronavirus Immunotherapy Consortium (CoVIC)


The world is in need of a solution to COVID-19.

COVID-19

The world is in need of a solution to COVID-19. We’re honored to be the provider of high-throughput antibody screening and characterization data to CoVIC. They have the most ambitious research goals and aggressive timelines. The Carterra LSA is the right tool at the right time.

Carterra® Inc., the world leader in high-throughput antibody screening and characterization tools, and La Jolla Institute for Immunology (LJI), announced today that they will use Carterra’s proprietary LSA™ platform to screen hundreds of antibodies in just a few days allowing CoVIC to move therapeutic candidates to the clinic as early as this summer.

La Jolla Institute for Immunology (LJI) has been awarded a $1.73 million grant by the Bill & Melinda Gates Foundation to establish a Coronavirus Immunotherapy Consortium (CoVIC) as part of the foundation’s global efforts to stem the tide of the current coronavirus outbreak, the Institute announced yesterday. Antibody therapies are often the first novel therapies advanced for an emerging infectious disease.

Headquartered at LJI, CoVIC will serve as a clearinghouse to understand which antibodies are most effective against the novel coronavirus SARS-CoV-2 and to accelerate the research pipeline to provide immunotherapeutics in order to protect vulnerable individuals from severe manifestations of COVID-19 in all parts of the world including low-resource settings.

This effort is being funded as part of the COVID-19 Therapeutics Accelerator launched in early March by the Gates Foundation, Wellcome, and Mastercard. The Accelerator provides fast and flexible funding at key stages of the development process to de-risk the pathway for drugs and biologics to prevent and treat COVID-19.

The effort is led by Erica Ollmann Saphire, Ph.D., a professor in LJI’s Center for Infectious Disease and Vaccine Research, who draws on her broad research experience guiding the development of antibody drugs and galvanizing a global research coalition that helped define which therapeutic antibodies effectively combat disease in humans infected with Ebola virus.

“We are thrilled that Carterra will provide full antibody characterization data using affinity measurements and, potentially more importantly, ultra-high resolution information of the epitopes,” says Dr. Ollmann Saphire. “Knowing how well these antibodies bind to the target is important but understanding their mechanism of action and how different antibodies can complement each other will determine what ends up in the clinic.”

Traditional antibody discovery requires a primary screen of ever-expanding antibody libraries. Only a small group of candidate antibodies are then characterized on traditional, low-throughput, low-resolution biosensor tools which provide real-time readout of the binding profile. This workflow runs the risk that potential drug candidates could be missed or that the process of candidate selection could be exceedingly long.

Carterra’s LSA is turning that model on its head by enabling the high-resolution analysis of entire libraries, combining screening and characterization into one seamless step, thereby minimizing the risk of missing a potent therapeutic candidate. The LSA’s dramatic throughput condenses months of work into days. Infectious diseases are ideal for leveraging the power of the LSA platform as evidenced in recent studies of Yellow Fever and Ebola where the LSA helped elucidate the immunity of survivors.

Additionally, the LSA platform offers investigators the most resolved view of the epitope – the location an antibody binds to its target. An epitope is an innate property that cannot be changed and must be discovered empirically. The LSA is the only technology that enables characterization of epitope binding at the full library level.

“The world is in need of a solution to COVID-19,” says Josh Eckman, Carterra’s Chief Executive Officer. “We’re honored to be the provider of high-throughput antibody screening and characterization data to CoVIC. They have the most ambitious research goals and aggressive timelines. The Carterra LSA is the right tool at the right time.”

About Carterra, Inc.

Carterra® is the leading provider of high throughput technologies designed to accelerate and improve the discovery of novel therapeutic candidates. Carterra’s LSA™ instrument, software, and consumables for monoclonal antibody (mAb) characterization deliver up to 100 times the throughput of existing platforms in 10% of the time while using only 1% of the sample required by other systems. The LSA combines patented microfluidics technology with real-time high throughput Surface Plasmon Resonance (HT-SPR) and industry-leading data analysis and visualization software to revolutionize mAb screening. Carterra, Inc. is based in Salt Lake City Utah, and has Customer Experience Centers in Dublin, California, Boston, Massachusetts, and Munich, Germany. For additional information, please visit: http://www.carterra-bio.com

About La Jolla Institute for Immunology

La Jolla Institute for Immunology is dedicated to understanding the intricacies and power of the immune system so that we may apply that knowledge to promote human health and prevent a wide range of diseases. Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading towards its goal: life without disease®.

Share article on social media or email:

Scale Computing Offers Acronis Cloud Storage, Expands Storage Options for Enhanced Data Backup, Disaster Recovery, and Ransomware Mitigation


News Image

Scale Computing, a market leader in edge computing, virtualization and hyperconverged solutions, today announced it is offering Acronis Cloud Storage, adding a further dimension to the existing OEM partnership with the global leader in cyber protection. The easy to use cloud subscription from Acronis gives Scale Computing HC3 customers a powerful, highly available, hybrid redundant backup storage solution delivering disaster recovery protection and cyberthreat mitigation.

By offering Acronis Cloud Storage, Scale Computing provides customers with a safe, secure and easy place to back up data. By integrating the Scale Computing HC3 platform with Acronis Cyber Backup, users can benefit from a wide range of advanced backup and protection features, including granular object-level recovery, variable-length deduplication for backups, and active ransomware protection.

The new end-to-end storage and cloud backup solution can protect entire virtual machines (VMs), providing bare-metal restore capabilities, and can restore to dissimilar hardware or platforms if required. Available to purchase in one- or three-year terms, Scale Computing will be offering Acronis Cloud Storage in increments ranging from 250GB to 5TB.

Acronis backups are stored on reliable Acronis Cyber Infrastructure (a secure software-defined compute and storage solution) with outstanding redundancy and error correction. The data center infrastructure is designed around high availability and redundancy to minimize associated risks and eliminate single points of failure. In addition, physical security is ensured through several protective measures such as security barriers, video surveillance, and highly monitored access. Data can also be encrypted at source with government-approved AES-256 strong encryption before sending it to a secure data center.

“We are seeing considerable demand from today’s businesses for data protection, backup and disaster recovery. Integrating the Scale Computing HC3 platform with Acronis will help customers meet these priorities in a simple and cost-effective way,” explained Jeff Ready, CEO and co-founder, Scale Computing. “Scale Computing customers can now easily and securely store their Acronis backups locally or in the cloud, with a scalable solution that is designed for agile businesses.”

“The ever-rising threat of ransomware and other cyberthreats along with changing IT requirements have organizations facing ongoing challenges associated with protecting their infrastructure. Due to this, more organizations are demanding cyber protection solutions that are easy, efficient and secure for backing up their data,” said Patrick Hurley, Vice President and General Manager, Americas at Acronis. “With Acronis Cloud Storage on Scale Computing HC3, organizations gain a high availability data protection cloud solution that also ensures safe, secure and scalable offsite backup for any data or any system — anytime, anywhere.”

Availability:

Acronis Cloud from Scale Computing is available now, worldwide.For more information about Acronis Cloud Storage on Scale Computing HC3, visit: https://www.scalecomputing.com/acronis

About Scale Computing

Scale Computing is a leader in edge computing, virtualization, and hyperconverged solutions. Scale Computing HC3 software eliminates the need for traditional virtualization software, disaster recovery software, servers, and shared storage, replacing these with a fully integrated, highly available system for running applications. Using patented HyperCore™ technology, the HC3 self-healing platform automatically identifies, mitigates, and corrects infrastructure problems in real-time, enabling applications to achieve maximum uptime. When ease-of-use, high availability, and TCO matter, Scale Computing HC3 is the ideal infrastructure platform. Read what our customers have to say on Gartner Peer Insights, Spiceworks, TechValidate and TrustRadius.

About Acronis

Acronis sets the standard for cyber protection through its innovative backup, anti-ransomware, disaster recovery, storage, and enterprise file sync and share solutions. Enhanced by its award-winning AI-based active protection technology, blockchain-based data authentication and unique hybrid-cloud architecture, Acronis protects all data in any environment – including physical, virtual, cloud, mobile workloads and applications – all at a low and predictable cost.

Founded in Singapore in 2003 and incorporated in Switzerland in 2008, Acronis now has more than 1,500 employees in 33 locations in 18 countries. Its solutions are trusted by more than 5.5 million consumers and 500,000 businesses, including 100% of the Fortune 1000 companies. Acronis’ products are available through 50,000 partners and service providers in over 150 countries in more than 30 languages.

Share article on social media or email:

Flagship Biosciences Hires New Vice President of Clinical Diagnostics


Photo of Geoff Metcalf, MBA, PMP, new Vice President Clinical Diagnostics at Flagship Biosciences

Geoff Metcalf, MBA, PMP, is new Flagship Biosciences Vice President Clinical Diagnostics

Flagship clients already benefit from the company’s scientific process enhanced by machine learning, and from its laboratory capabilities and tissue analysis technology. I’m excited to build on this strong foundation to bring new diagnostic tissue tests to market.

Flagship Biosciences, providers of expert tissue data insights, today announced that Geoff Metcalf, MBA, PMP, will join its executive team as Vice President Clinical Diagnostics. Geoff brings 25 years of experience in developing and commercializing diagnostic tests and medical devices. In his new role, Geoff will lead the creation and implementation of diagnostic tissue tests utilizing Flagship’s unique tissue analysis technology, workflow, and CAP/CLIA lab.

Geoff has served in a variety of leadership roles from strategic planning and product development to sales and marketing and business development. His background includes successes with industry leaders Eli Lilly, Siemens, and Beckman Coulter, and most recently with start-up organizations, creating businesses based on novel technologies. Geoff earned a BS in Chemical Engineering from Virginia Tech and an MBA from Harvard University.

“It’s my pleasure to welcome Geoff to the Flagship family,” said Trevor Johnson, Flagship Biosciences CEO. “Geoff’s broad industry experience and specifically in preparing and marketing diagnostic tests make him the perfect new leader for our growing clinical diagnostics business unit.”

Flagship already supports diagnostic labs, cancer centers, and academic medical centers with tissue data insights gained in its College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified lab. Geoff will expand these offerings for clinical clients and partners.

“I couldn’t be happier about joining Flagship to expand clinical diagnostics,” said Geoff. “Flagship clients already benefit from the company’s scientific process enhanced by machine learning, and from its laboratory capabilities and tissue analysis technology. I’m excited to build on this strong foundation to bring new diagnostic tissue tests to market.”

About Flagship Biosciences

Founded in 2009 and headquartered in Westminster, Colorado, Flagship Biosciences, Inc. is a technology-driven tissue analysis services company delivering the most accurate and informative data available. It is revolutionizing tissue analysis to improve drug development and diagnostics using the power of AI with a consultative approach. Flagship’s services and technology dramatically improve on the data and interpretation from traditional pathology methods, eliminating variability and bringing new insights to tissue analysis results. With expert scientific consultation on every project, Flagship’s team interprets results, contextualizes tissue biology, and identifies the best course for success. flagshipbio.com

Share article on social media or email:

Acumed Welcomes Acute Thoracic Products to its Portfolio of Orthopaedic Solutions


“The integration of Acute allows Acumed to expand on the delivery of these premium products to all of our surgeon customers in general trauma, orthopaedic trauma, and thoracic surgery.”

Acumed is excited to welcome Acute Innovations, a manufacturer of innovative solutions for challenging traumatic chest wall injuries, to join us in developing industry-first products and sharing our commitment to Education, Evidence, Innovation, and Quality. The Acute product portfolio specifically offers surgeons solutions to address rib fractures associated with traumatic injury, as well as technologies for chest wall reconstruction.

Acute’s thoracic solutions will be integrated into the operations of Acumed to fully leverage the infrastructure and optimize best practices in quality affairs, marketing, medical education, manufacturing, and finance. The Acute product line has enjoyed robust growth through its innovative and clinically compelling solutions: the RibLoc® chest wall plating system, the BioBridge® resorbable chest wall stabilization plate, and the AcuTie® II sternum closure system.

“Acute Innovations has observed solid growth and clinical support in its family of products. The integration within Acumed will immediately recognize operational synergies. This integration allows Acumed to expand on the delivery of these premium products to all of our surgeon customers in general trauma, orthopaedic trauma, and thoracic surgery,” commented Jagi Gill, Vice President of Business Development for Acumed.

Sharon Wolfington, President and CEO of Acumed, added, “Over the past 30 years, Acumed has earned a reputation for delivering innovative and high-quality extremity fixation products. The addition of rib fracture fixation and chest wall stabilization and reconstruction products will further enhance our ability to support surgeons who treat patients in their time of need.”

About Acumed

Acumed is a global leader in developing innovative orthopaedic and medical solutions to improve patient care. Acumed has more than three decades of experience in the orthopaedic industry, with the mission of aiding the afflicted through the ingenuity of our minds, the labor of our hands, and the compassion of our hearts. Founded in 1988, Acumed is headquartered in Hillsboro, Oregon, with offices and a distribution network around the world. For more information, visit http://www.acumed.net.

Share article on social media or email: